PDF Cover

Avibactam Market

Avibactam Market

The market for Avibactam was estimated at $840 million in 2024; it is anticipated to increase to $1.25 billion by 2030, with projections indicating growth to around $1.73 billion by 2035.

Report ID:DS1802580
Author:Debadatta Patel - Senior Consultant
Published Date:November 2025
Datatree
Life Science
Pharmaceutical
Avibactam
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Avibactam Market Outlook

Revenue, 2024

$840M

Forecast, 2034

$1.62B

CAGR, 2024 - 2034

6.8%
The Avibactam industry revenue is expected to be around $897.5 million in 2025 and expected to showcase growth with 6.8% CAGR between 2025 and 2034. The growing popularity of Avibactam in the market is supported by crucial factors driving its success forward. Primarily driven by its expanding application in the healthcare sector to address antibiotic infections that are increasingly prevalent nowadays; it fulfills a vital role in safeguarding patient well being and hence accentuating its market value significantly. Furthermore the progress in research and development activities along, with awareness and favorable regulatory environments are additional factors contributing to its importance.

Avibactam stands out as a cutting edge lactam beta lactamase inhibitor with a crucial capability that enables it to combat a wide variety of resilient pathogens effectively. One of its uses involves working together with antibiotics like ceftazidime to broaden the range of attacks against Gram negative bacteria that are resistant to third generation cephalosporins. The growing challenge of resistance alongside the emergence of new Avibactam formulations has fueled the recent surge in demand, for this innovative solution.

Avibactam market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Avibactam market is projected to grow from $840.4 million in 2024 to $1.62 billion in 2034. This represents a CAGR of 6.8%, reflecting rising demand across Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

  • Pfizer Inc, AstraZeneca Plc, and Johnson & Johnson are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Avibactam market and are expected to observe the growth CAGR of 4.4% to 6.5% between 2024 and 2030.
  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 7.8% to 9.4%.

  • Transition like Expansion into Generic Market is expected to add $105.1 million to the Avibactam market growth by 2030

  • The Avibactam market is set to add $782 million between 2024 and 2034, with manufacturer targeting Research Laboratories & Pharmaceuticals Application projected to gain a larger market share.
  • With

    surge in antimicrobial resistance, and

    increase in healthcare expenditure, Avibactam market to expand 93% between 2024 and 2034.

avibactam market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Avibactam

The pharmaceutical sector is also well known for forming partnerships to expand business reach and broaden product offerings. With the effectiveness of Avibactam in combating infections that are also resistant, to multiple drugs potential exists for pharmaceutical companies to form valuable collaborations and work together to maximize the benefits of Avibactam.

Growth Opportunities in North America and Europe

North America Outlook

In the American market sector of healthcare services and medications usage trends have markedly shown a rise in the prominence of Avibactam as a crucial weapon in combating bacteria resilient to antibiotics treatments that are currently available in the market today. The regions established healthcare system and strict regulatory procedures have contributed significantly to an increased need for this antibacterial medication within the population. Growing awareness surrounding the effects associated with Avibactams therapeutic applications along with an escalating incidence rate of bacterial strains resistant to multiple drugs serve as key drivers behind its surging demand. Furthermore the active participation of recognized pharmaceutical companies further intensifies competition within this sector leading to a continuous stream of new innovations, in drug development and manufacturing processes.

Europe Outlook

In contrast to this perspective is how Avibactams market is evolving in Europe – driven significantly by the increasing population and a well established network of research institutions in the region that fuels market growth potential for Avibactam. The pharmaceutical industry in Europe plays a role in boosting the outlook for Avibactam by fostering a competitive market landscape where it can flourish. Moreover the strict regulatory framework, in Europe promotes the adoption of Avibactam to combat the rise of antibiotic infections elevating its utilization to unprecedented levels.

Market Dynamics and Supply Chain

01

Driver: Surge in Antimicrobial Resistance, and Rapid Technological Advancements in Drug Discovery

The increase in resistance on a worldwide scale has also greatly emphasized the necessity for fresh and efficient antibiotics such as Avibactam. This resistance poses a threat to push medicine back to the time before antibiotics existed by weakening our ability to combat everyday infections. Avibactam acts as a β inhibitor that reinstates the effectiveness of antibiotics particularly against bacteria resistant to multiple drugs. Therefore the surge in resistance is also leading to a strong need which is also boosting the demand for Avibactam, in the market.

Technological advancements expedite drug discovery processes and enable researchers to identify novel compounds and mechanisms. This progress, in turn, impacts Avibactam market positively that resulted from a cutting-edge drug discovery method. Such advancements ensure a continuous pipeline of innovative drugs like Avibactam, propelling its demand in the market.


The increasing expenditure on healthcare globally is also boosting the market prospects of Avibactam drug significantly The availability and affordability of medications such as Avibactam are also getting better with extensive investments in the healthcare industry The remarkable efficacy of this medication in combating bacterial infections has also resulted in its inclusion in various national formularies This has also further fueled the demand for Avibactam, in the market.

02

Restraint: High Drug Development Costs

The creation and evaluation of medications such as Avibactam require a financial commitment. This procedure encompasses phases, like investigation studies, medical experiments and official clearances which demand extensive resources and time. Expensive investments may restrict the manufacturing capacity and availability of the medication thereby hindering market expansion.

03

Opportunity: Harnessing Untapped Market Segments and Advancements in Technological Innovations

Avibactams strong inhibitory effect on beta lactamase enzymes in the field positions it as a valuable remedy against stubborn bacterial infections that are becoming increasingly resistant to traditional treatments worldwide. Given the escalating challenge of resistance on a global scale the demand for potent antibacterial solutions such, as Avibactam is growing, creating an opportunity to explore and establish presence in a new market segment.


Projections suggest that with the advancement of drug formulations and innovative delivery methods the utilization of Avibactam could see a significant boost in potential benefits. Technological advancements are opening up avenues for formulating variations that have the capacity to enhance the effectiveness and scope of Avibactams therapeutic applications—an encouraging prospect, for business growth potential.

04

Challenge: Stringent Regulatory Guidelines

Drug development is heavily regulated by bodies like the FDA to ensure patient safety. Compliance with these rigorous standards can slow down the timeline of drug launch. This can directly impact the availability of Avibactam in the market which could potentially impede its market growth.

Supply Chain Landscape

1
Raw Material Suppliers

Pfizer

AstraZeneca

2
Intermediate Manufacturers

Teva Pharmaceuticals

Mylan N.V

3
API Producers

Allergan Plc

Durata Therapeutics

4
Formulations & Drug Providers

Novartis AG

Johnson & Johnson

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Avibactam in Hospital Pharmacies, Retail Pharmacies & Online Pharmacies

Hospital Pharmacies

Avibactam, commonly applied in a combination with ceftazidime, has broad-spectrum utilization in hospital pharmacies. This combinatorial drug demonstrates substantial effectiveness against Gram-negative infections. Top market players in this scope include AstraZeneca and Pfizer, both renowned names in pharmaceuticals, rendering a strong market position.

Retail Pharmacies

Avibactam has key application in the retail pharmaceutical sector. Its inclusion in antibiotics fends off bacterial resistance and ensures a high efficacy rate. Companies have recognized this advantage, with Teva Pharmaceuticals and Novartis being the leaders in this field due to their wide product range and geographical outreach.

Online Pharmacies

With the rise of e-commerce, Avibactam has found effective utilization in online pharmacies. Utilized in products aimed at treating severe bacterial infections, its usage in the digital realm is growing. Key players in this domain include names such as Walmart and Amazon who bring vast customer base and rigorous expansion strategies to the table.

Recent Developments

December 2024

Advanomics Pharmaceuticals announced a breakthrough in Avibactam production, utilizing patented synthesis methods that increase yield by 30%

October 2024

The FDA approved Biolytic Laboratories Avibactam-based combo drug for treatment-resistant urinary tract infections

August 2024

GenHealth Solutions declared significant success in phase II clinical trials of their Avibactam formulation for severe hospital-acquired pneumonia.

Avibactam, an antibiotic adjuvant notorious for its potent antimicrobial properties, stands at the forefront of the healthcare industry's triumph against various kinds of bacterial infections. The advancements in Avibactam-focused research and regulatory approvals have been pivotal in steering the pharmaceutical sector in unprecedented ways.

Impact of Industry Transitions on the Avibactam Market

As a core segment of the Pharmaceutical industry, the Avibactam market develops in line with broader industry shifts. Over recent years, transitions such as Expansion into Generic Market and Advancements in Drug Combination Therapies have redefined priorities across the Pharmaceutical sector, influencing how the Avibactam market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expansion into Generic Market

In the few years there has been a noticeable change in the Avibactam sector as it makes its way into the generic drug market more and more. The expiration of patents related to Avibactam has led to an uptick in the economy focused generics market. This shift has played a role in making antimicrobial treatments more affordable and available. Moreover this transformation in the market dynamics has encouraged pricing strategies expanding the range of consumers interested, in Avibactam products. This industry transition is expected to add $105.1 million in the industry revenue between 2024 and 2030.
02

Advancements in Drug Combination Therapies

Another significant industry transition centers on the progressively common pairing of Avibactam with other antimicrobials, specifically ceftazidime. This development in combination therapies has revolutionized the treatment of complex infections, especially those resistant to monotherapies. The resultant ceftazidime-avibactam fusion has exhibited greater effectiveness against multi-drug resistant bacterial strains. Consequently, this industry transition carries implications for the broader pharmaceutical sector in improving patient outcomes.

Report Price: $4,200

Related Reports

Loading related reports...